Summary

Authorizes new annual funding for the federal cell transplantation program by listing $31,009,000 as the existing appropriation and adding $33,009,000 per year for fiscal years 2027–2031. It also changes the statutory language governing the national cord blood inventory, but the specific replacement text was not provided, so the concrete effects of that amendment are unclear. The bill updates the funding authority for the C.W. Bill Young Cell Transplantation Program and clarifies multi-year authorization levels; actual funding still requires future appropriations by Congress. The unspecified change to the cord blood inventory statute creates uncertainty about programmatic or operational impacts until the new language is available.

Key Points

• Adds an explicit annual authorization of $33,009,000 for FY2027–FY2031 for the C.W. Bill Young Cell Transplantation Program.
• Preserves and restates the existing $31,009,000 appropriation figure while adding the new multi-year authorization.
• Amends the law governing the national cord blood inventory, but the replacement text was not provided so exact effects are unknown.
• This is an authorization change — actual funding requires later action in appropriations legislation.
• The annual authorized increase is $2,000,000 over the previously cited figure.
• Primarily affects federal stem cell/cell transplantation and cord blood programs rather than creating new programs.
• Short, narrowly focused bill with limited procedural and policy complexity.
• Uncertainty remains until the amended cord blood inventory language is available and appropriations are made.

Categories & Tags